1 / 7

Research report covers Neuroendocrine Carcinoma Market share and Growth, 2016-2026

Neuroendocrine tumors (NETs) are malignant tumors that originate in endocrine cells and targets digestive tract that misbalances hormonal release. Neuroendocrine tumors are three types which include Pheochromocytoma, Merkel cell cancer, and neuroendocrine carcinoma. Neuroendocrine cells also present in the neuroendocrine system that includes pituitary gland, pineal gland, thyroid gland, parathyroid and adrenal glands. Physiological changes in the neuroendocrine cells may cause formation of two types of tumors–functional and nonfunctional tumors. Functional tumors develop another endocrine cells and nonfunctional tumors may cause physiological changes and based on the cause it treated. Neuroendocrine carcinoma are classified in two categories namely carcinoids and pancreatic endocrine tumors.

fmiresearch
Download Presentation

Research report covers Neuroendocrine Carcinoma Market share and Growth, 2016-2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Neuroendocrine Carcinoma Market Share, Global Trends, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2016 Future Market Insights www.futuremarketinsights.com sales@futuremarketinsights.com

  2. Future Market Insights (FMI) is apremier provider of syndicated research reports, custom research reports, andconsulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technologyinputs,valuablegrowthinsights,aerialviewofthecompetitiveframework,andfuturemarkettrends. Weprovideresearchservicesat aglobalas wellas regionallevel;keyregionsincludeGCC, ASEAN,andBRIC. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and Retail. We have a global presence with delivery centers across India specializing in providing global research reports and country research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for our client. Research Capabilities Sector Coverage  Automotive and Transportation  Electronics, Semiconductor, and ICT  Retail and Consumer Products  Industrial Automation and Equipment  Customized Research  Syndicated Research  Investment Research  Social Media Research  Chemicals & Materials  Food and Beverages  Services and Utilities  Energy, Mining, Oil, and Gas Customized Research Subscription Information Syndicated Research For detailed subscription information please contact Hari. T (Sr. Manager -Global Business Development) Investment Research T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268 Email: hari.t@futuremarketinsights.com Social Media Research

  3. Report Description Report Description Neuroendocrine tumors (NETs) are malignant tumors that originate in endocrine cells and targets digestive tract that misbalances hormonal release. Neuroendocrine tumors are three types which include Pheochromocytoma, Merkel cell cancer, and neuroendocrine carcinoma. Neuroendocrine cells also present in the neuroendocrine system that includes pituitary gland, pineal gland, thyroid gland, parathyroid and adrenal glands. Physiological changes in the neuroendocrine cells may cause formation of two types of tumors– functional and nonfunctional tumors. Functional tumors develop another endocrine cells and nonfunctional tumors may cause physiological changes and based on the cause it treated. Neuroendocrine carcinoma are classified in two categories namely carcinoids and pancreatic endocrine tumors. Carcinoid tumors, originating in the neuroendocrine system, usually appear in the digestive system i.e. in stomach and appendix. Besides, some carcinoid tumors develop in other organs such as lungs, thymus and ovaries. Due to their gradual growth, the symptoms of neuroendocrine carcinoma are not visible at early stages and are discovered only during undergoing an unrelated surgery. Tumors originating in the pancreas are named depending on the type of hormone released. For example, a tumor called gastrinoma is a tumor that release gastrin which results in excessive secretion of gastric acid. Request free sample Report: http://www.futuremarketinsights.com/reports/sample/rep- gb-1278

  4. Report Description Report Description Surgery is the first line therapy for removing affected neuroendocrine cells, thereafter, medication is used for treating neuroendocrine carcinoma. Sunitinib and Afinitor drugs are commonly used drugs for treatment of neuroendocrine carcinoma treatment. Immune system suppression and exposure to arsenic are the major risk factors for neuroendocrine carcinoma. Neuroendocrine Carcinoma Market: Drivers and Restraints Significant increase in funding for treatment of cancer by various international organizations such as American Cancer Academy and world Health Organization is expected to boost overall neuroendocrine carcinoma treatment market. Furthermore, significant increase in healthcare spending along with high prevalence rate of neuroendocrine carcinoma in developing region is expected to boost overall neuroendocrine carcinoma market. Though market is expected to witness healthy growth, lack of skilled healthcare professional and lower adoption of advanced treatment technologies in the developing economies are key restrains for neuroendocrine carcinoma market. Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1278 Neuroendocrine Carcinoma Market: Segmentation Neuroendocrine Carcinoma market further segmented into followingtype.

  5. Report Description Report Description By Treatment • Surgery • Medication • Anti-metabolite • Platinum derivatives • Topoisomerase inhibitor • Anthracycline antibiotic By End User • Hospital • Clinics • Drug store • Pharmacies Neuroendocrine Carcinoma Market: Overview Neuroendocrine tumors (NETs) are malignant tumors that originate in endocrine cells and targets digestive tract that misbalances hormonal release. The market is expected to witness healthy CAGR during the forecast period.

  6. Report Description Report Description Browse full report: http://www.futuremarketinsights.com/reports/neuroendocrine- carcinoma-market Neuroendocrine Carcinoma Market: Region- wise Outlook The global Neuroendocrine Carcinoma Market is expected to register a impressive CAGR over the forecast period. Depending on geographic regions, global neuroendocrine carcinoma market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa North America dominates the global neuroendocrine carcinoma market owing to presence of modern healthcare amenities along with significant healthcare expenditure in these regions. Europe occupies second place in this market with its new regulations in the major economies. Asia also shows a healthy growth rate in this market. Neuroendocrine Carcinoma Market: Key Players Some of the key players in this market include • Novartis AG • F. Hoffman La Roche • Callisto Pharmaceuticals • Eli Lilly & Company

  7. Thank You! To know more about us, please visit our website: www.futuremarketinsights.com For sales queries or new topics email us on: sales@futuremarketinsights.com For other queries contact: Mr. Sudip Saha Future Market Insights: 616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989, United States T: +1-347-918-3531 | D: +1-845-579-5705

More Related